Skip to main content
Premium Trial:

Request an Annual Quote

Lung Cancer Study Under Fire

Premium

It's a well-known fact that researchers who want to conduct experiments on human subjects must get informed consent from each of the partcipants, acknowledging the risks of said experiments, says The New York Times' Gardiner Harris. But the researchers who conducted a "controversial" and "widely publicized" lung cancer study in 2006, which involved more than 50,000 participants, say they can't locate about 90 percent of the consent forms, Harris says. The trial, led by researchers at Weill Cornell Medical College, concluded that 80 percent of lung cancer deaths could be prevented if doctors more widely screened patients with CT scans. The trial drew criticism and skepticism, especially when it came to light in 2008 that the study had been financed in large part by a cigarette maker, Harris says. At the time, critics of the study said they couldn't find out whether informed consent was obtained, or whether the forms were lost. A spokesman for Weill Cornell says all federal research regulations were followed, Harris adds. The journal The Oncologist, which published the study, says that if there was no informed consent from the patients in the study, then the paper would have to be retracted.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.